Cost-Effectiveness Analysis of Peginterferon Beta-1a In Italian Relapsing Remitting Multiple Sclerosis Management.
نویسندگان
چکیده
Milan, Italy Cost-Effectiveness Analysis of Peginterferon Beta-1a in Italian Relapsing-Remitting Multiple Sclerosis Management Iannazzo S,1 Santoni L,2 Saleri C,2 Puma E,2 Vestri G,2 Giuliani L,1 Canonico PL,3 Centonze D4 1SIHS Health Economics Consulting, Torino, Italy; 2Biogen Italia, Milan, Italy; 3Department of Pharmaceutical Sciences, University of Eastern Piedmont, Novara, Italy; 4Centre for Multiple Sclerosis, Tor Vergata University, Rome, Italy, and Istituto Neurologico Mediterraneo Neuromed, Pozzilli (Isernia), Italy
منابع مشابه
Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data
Health technology The study examined five treatments for patients with relapsing-remitting multiple sclerosis (MS). These comprised symptomatic management (physical therapy and pharmacological treatment for symptom management) alone, or symptomatic management supplemented by four alternative immunomodulatory therapies. The immunomodulatory therapies were subcutaneous (SC) glatiramer acetate (GA...
متن کاملAcute Liver Dysfunction Associated With Interferon-Beta-1a (Avonex®) Use in A Young Female Patient with Relapsing-Remitting Multiple Sclerosis (RRMS)
Background: It has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. We report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (Avonex®) intramuscular inje...
متن کاملImprovement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis
BACKGROUND Subcutaneous peginterferon beta-1a every 2 weeks significantly affects clinical outcomes in patients with relapsing-remitting multiple sclerosis (RRMS). OBJECTIVES To explore relationships between relapses and worsening of disability in patients with RRMS, and assess the treatment effect of peginterferon beta-1a on relapse recovery. METHODS Post-hoc analysis of the 2-year, random...
متن کاملA post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients.
BACKGROUND Interferon beta 1b (Betaferon) and 1a (Avonex) were licensed in Italy for treating relapsing-remitting multiple sclerosis in February 1996 and August 1997, respectively. OBJECTIVES To evaluate the effectiveness of these agents on the basis of clinical experience in northern Italian multiple sclerosis centres. DESIGN Clinical data on patients with relapsing-remitting multiple scle...
متن کاملThe Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
BACKGROUND Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with interferon beta (IFN beta) can develop neutralizing antibodies (NAbs) that reduce treatment efficacy. Several clinical studies explored the association of NAb+ status with increased disease activity. OBJECTIVE The aim of this study was to estimate the cost of RRMS patients who develop NAbs while treated with IFN be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 18 7 شماره
صفحات -
تاریخ انتشار 2015